18th Annual Greenebaum Lecture Highlights Innovation in HIV Prevention and Virology

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine hosted its 18th Annual Greenebaum Lecture, bringing together researchers, clinicians, students, and community members for an engaging discussion on the future of HIV prevention and viral research.

This year’s lecture featured two distinguished speakers from Gilead Sciences: Moupali Das, MD, MPH, and Anu Osinusi, MD, MPH, who shared cutting-edge insights into how scientific innovation is reshaping the global response to infectious diseases.

Dr. Das presented “Lenacapavir for HIV Prevention: The PURPOSE Program,” highlighting the promise of long-acting HIV prevention therapies. Her talk explored how advances like lenacapavir could transform prevention strategies, improve adherence, and expand options for populations at highest risk—marking a significant step forward in the effort to end the HIV epidemic.

Dr. Osinusi followed with “Viruses Don’t Wait: Innovation Across Virology,” offering a broader perspective on the rapidly evolving landscape of viral research. She discussed breakthroughs in hepatitis, respiratory viruses, and emerging infectious threats, emphasizing the urgency of innovation and collaboration to stay ahead of global health challenges.

The Greenebaum Lecture continues to serve as a cornerstone event for IHV, fostering dialogue at the intersection of science, clinical care, and public health. Attendees praised the speakers for their clarity, vision, and commitment to translating research into real-world impact.

IHV extends sincere thanks to Drs. Das and Osinusi, as well as to all attendees and partners, for advancing the conversation on virology and global health—and for reinforcing the importance of innovation in addressing today’s most pressing infectious disease challenges.